Last reviewed · How we verify
FEIBA- Activated Prothrombin Complexes
FEIBA, an Activated Prothrombin Complexes product marketed by Sheba Medical Center, holds a significant position in the treatment of bleeding disorders. The key composition patent for FEIBA is set to expire in 2028, providing a strong competitive advantage until then. The primary risk is the potential for increased competition post-patent expiry.
At a glance
| Generic name | FEIBA- Activated Prothrombin Complexes |
|---|---|
| Sponsor | Sheba Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (PHASE3)
- Treatment of Hemophilia A Patients With FVIII Inhibitors
- FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR) (PHASE3)
- FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients (PHASE2)
- Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors (PHASE2, PHASE3)
- Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed
- Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FEIBA- Activated Prothrombin Complexes CI brief — competitive landscape report
- FEIBA- Activated Prothrombin Complexes updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI